RxDoctor Payments DataLook up a doctor →

Victor Faradji, MD

Neurology · Miami, FLNPI 1851354807

Payments from drug & device makers

$4,023,977in general payments, 2019–2025

Across 1,767 payments — averaging $2277.29 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Eli Lilly$1.7M
  • Eisai Inc.$1.4M
  • E.r. Squibb & Sons, L.L.C.$377K
  • Novo Nordisk AS$257K
  • AbbVie$110K
  • Acadia Pharmaceuticals Inc$58K
  • plus $30K from 54 others
$33,936in research payments, 2019–2025

Across 20 payments — averaging $1696.79 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$33K
  • Acadia Pharmaceuticals Inc$1K

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Eli Lilly61$1,749,728
Eisai Inc.316$1,441,037
E.r. Squibb & Sons, L.L.C.3$376,809
Novo Nordisk AS78$257,388
AbbVie(2 entities)275$110,243
Acadia Pharmaceuticals Inc51$58,008
Avanir Pharmaceuticals, Inc.14$5,445
UCB, Inc.60$2,383
AstraZeneca(2 entities)71$2,022
Amgen(2 entities)54$1,943
Otsuka Pharmaceutical Development & Commercialization, Inc.1$1,750
Teva Pharmaceuticals USA, Inc.62$1,444
Lilly USA, LLC56$1,330
Pfizer61$1,137
Biogen34$919
Neurocrine Biosciences, Inc.48$907
Lundbeck LLC40$900
Argenx US, Inc.31$749
Novartis32$701
Sanofi25$441
Amneal Pharmaceuticals LLC21$435
Adamas Pharmaceuticals, Inc.28$422
Sunovion Pharmaceuticals Inc.20$372
MDD US Operations, LLC10$358
Scilex Pharmaceuticals Inc.16$336
Acorda Therapeutics, Inc18$335
Merz Pharmaceuticals, LLC14$316
Otsuka America Pharmaceutical, Inc.15$301
Impel Pharmaceuticals Inc.20$296
Neurelis, Inc.15$292
Kyowa Kirin, Inc.8$264
Boston Scientific5$245
SK Life Science, Inc.11$237
Tanabe Pharma America, Inc.10$234
Biohaven Pharmaceutical Holding Company Ltd.12$229
Inspire Medical Systems, Inc.2$221
EMD Serono, Inc.7$203
Biohaven Pharmaceuticals, Inc.8$187
Johnson & Johnson(2 entities)7$182
Almatica Pharma LLC10$181
Zyla Life Sciences, Inc.13$180
Upsher-smith Laboratories LLC9$178
Alnylam Pharmaceuticals Inc.7$167
Akcea Therapeutics, Inc.3$148
Harmony Biosciences LLC3$147
Supernus Pharmaceuticals, Inc.10$144
Averitas Pharma Inc.4$135
Corium, LLC8$130
Revance Therapeutics, Inc.4$129
Mallinckrodt Hospital Products Inc.5$128
Idorsia Pharmaceuticals US Inc7$127
Novo Nordisk1$125
Takeda Pharmaceuticals U.S.A., Inc.4$121
CSL Behring4$107
Alfasigma USA, Inc.6$107
Axsome Therapeutics, Inc.4$105
Avion Pharmaceuticals6$97
C2n Diagnostics, LLC4$78
GE HealthCare4$72
TG Therapeutics, Inc.1$65

How this compares

$4,023,977 in reported general payments places this provider in the 95th percentile of 1,434 neurology providers in Florida.

See all neurology providers in Florida →

Medicare billing

Part B allowed, 2024
$432,226
Medicare patients
321
Services billed
115,524

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Miami

See the full list for Florida →

Where these figures come from

Is this you, or does something look wrong? →